Compare Sana Biotechnology Inc (SANA) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Vanguard S&P 500 Growth Index Fund ETF trades at $81.92. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VOOG | |
|---|---|---|
Market Cap | $873.84M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $5.92 | $85.11 |
52-Week Low | $2.68 | $65.32 |
Enterprise Value | $848.03M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
VOOG (Vanguard S&P 500 Growth ETF) trades at $80.98, up 0.28% with a bearish technical signal from moving averages. The ETF provides exposure to 212 large-cap growth stocks with a 0.07% expense ratio and heavy technology sector concentration. Recent news highlights comparisons with other growth ETFs, noting VOOG's strong long-term performance and competitive fee structure.
The outlook remains cautious due to bearish technical indicators and concentrated tech exposure, though the low expense ratio and S&P 500 growth focus provide structural advantages. Key risks include tech sector volatility and market sentiment shifts, while institutional interest remains steady given Vanguard's reputation and the ETF's track record.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
